Search results
Showing 31 to 36 of 36 results for dyslipidaemia
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.
Show all sections
Sections for NG246
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE recommended weight-loss drug to be made available in specialist NHS services
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.